Positron emission tomography-computed tomography in the diagnostic evaluation of smoldering multiple myeloma: identification of patients needing therapy.
Siontis B et al. Blood Cancer J. 2015 Oct 23;5:e364. doi: 10.1038/bcj.2015.87.
18F-FDG PET/CT FOCAL, but not osteolytic, lesions predict the progression of smoldering myeloma to active disease.
Zamagni E et al. Leukemia. 2015 Oct 22. doi: 10.1038/leu.2015.291. [Epub ahead of print].
MMSA-1 expression pattern in multiple myeloma and its clinical significance.
Meng S et al. Clin Exp Med. 2015 Oct 22. [Epub ahead of print].
A systematic study comparing aspirate versus trephine for quantifying plasma cell infiltration in newly-diagnosed myeloma.
Gabriel J et al. Br J Haematol. 2015 Oct 22. doi: 10.1111/bjh.13807. [Epub ahead of print].
Image interpretation criteria for FDG PET/CT in multiple myeloma: a new proposal from an Italian expert panel. IMPeTUs (Italian Myeloma criteria for PET USe).
Nanni C et al. Eur J Nucl Med Mol Imaging. 2015 Oct 16. [Epub ahead of print]
Minimal residual disease following autologous stem cell transplant in myeloma: impact on outcome is independent of induction regimen.
de Tute RM et al. Haematologica. 2015 Oct 15. pii: haematol.2015.128215. [Epub ahead of print].
Prognostic value of the inverse platelet to lymphocyte ratio (iPLR) in patients with multiple myeloma who were treated up front with a novel agent-containing regimen.
Jung SH et al. Ann Hematol. 2015 Oct 15. [Epub ahead of print].
Monocyte recovery at day 100 is associated with improved survival in multiple myeloma patients who undergo allogeneic hematopoietic cell transplantation.
Dhakal B et al. Bone Marrow Transplant. 2015 Oct 12. doi: 10.1038/bmt.2015.244. [Epub ahead of print].
Automatic recognition of myeloma cells in microscopic images using bottleneck algorithm, modified watershed and SVM classifier.
Saeedizadeh Z et al. J Microsc. 2015 Oct 12. doi: 10.1111/jmi.12314. [Epub ahead of print].
Aggressive and extramedullary plasma cell myeloma evade bone marrow flow cytometric minimal residual disease detection.
Came N et al. Br J Haematol. 2015 Oct 12. doi: 10.1111/bjh.13655. [Epub ahead of print].
Prospective molecular monitoring of minimal residual disease after non-myeloablative allografting in newly diagnosed multiple myeloma.
Ladetto M et al. Leukemia. 2015 Oct 6. doi: 10.1038/leu.2015.269. [Epub ahead of print].
Aberrant Levels of miRNAs in Bone Marrow Microenvironment and Peripheral Blood of Myeloma Patients and Disease Progression.
Wang W et al. J Mol Diagn. 2015 Nov;17(6):669-78. doi: 10.1016/j.jmoldx.2015.06.006. Epub 2015 Sep 30.
Clonotypic Light Chain Peptides Identified for Monitoring Minimal Residual Disease in Multiple Myeloma Without Bone Marrow Aspiration.
Robert Bergen H 3rd et al. Clin Chem. 2015 Oct 1. pii: clinchem.2015.242651. [Epub ahead of print].
Single Nucleotide Polymorphisms in TP53 but not KRAS or MDM2 are predictive of clinical outcome in multiple myeloma treated with High-Dose Melphalan and Autologous Stem Cell Support.
Gebauer N et al. Leuk Lymphoma. 2015 Sep 28:1-11. [Epub ahead of print].
Bone marrow micro-environmental CD4+ and CD8+ lymphocyte infiltration patterns define overall- and progression free survival in standard risk Multiple Myeloma – an analysis from the Austrian Myeloma Registry (AMR).
Willenbacher W et al. Leuk Lymphoma. 2015 Sep 28:1-11. [Epub ahead of print].
Laboratory testing requirements for diagnosis and follow-up of multiple myeloma and related plasma cell dyscrasias.
Willrich MA et al. Clin Chem Lab Med. 2015 Oct 28. pii: /j/cclm.ahead-of-print/cclm-2015-0580/cclm-2015-0580.xml. doi: 10.1515/cclm-2015-0580. [Epub ahead of print].